| Therapeutic | Abelacimab |
| Target | F11 |
| Heavy Chain | QVQLLESGGGLVQPGGSLRLSCAASGFTFSTAAMSWVRQAPGKGLEWVSGISGSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELSYLYSGYYFDYWGQGTLVTVSS |
| Light Chain | QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNDVSWYQQLPGTAPKLLIYKNYNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCSAWDQRQFDVVFGGGTKLTVL |
| 100% seqID Fv Structure | 6r8x [Fvs: CB] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 6r8x [Fvs: CB] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (August '23) | Phase-III |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | |
| INN Year Proposed | 2018 |
| INN Year Recommended | 2019 |
| Companies Involved | Novartis, Anthos Therapeutics, Labcorp Drug Development, TIMI Study Group |
| Conditions Approved | na |
| Conditions Active | Venous Thromboembolism, Stroke, Thrombosis |
| Conditions Discontinued | na |
| Notes | Feb '22: Added in missing residues 97 and 98. (Jun '22) Added missing residues at start of VL CDR3. |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
